Attack on Roche! Atezolizumab slams PD-L1 drug market September 6, 2015 Source: Medical Network With the introduction of PD-1 drugs by Squibb and Merck, the tumor immunotherapy market quickly set off a new storm. And another biomedical giant, Roche, is not to be outdone. Recently, the company announced that its development of the PD-L1 drug atezolizumab has achieved great success in a clinical phase II study for the treatment of non-small cell lung cancer. The company will use this result to seek accelerated approval from the FDA to catch up with the previous Opdivo. (Squibb) and Keytruda (Mussa East). Adult diapers are disposable urinary incontinence products, one of the adult care products, and a disposable diaper mainly suitable for incontinent adults. Adult Diapers Cvs,Adult Underwear,Adult Diapers Amazon,Adult Diapers For Women Shandong Kangshun Daily Products Co., Ltd , https://www.centurybenifit.com
Most products are flaky and shorts type. Use adhesive sheets to connect into a pair of shorts. The adhesive sheet also has the function of adjusting the waist size so as to fit different fat and thin body shapes.
Generally, the structure of diapers is divided into three layers from the inside to the outside. The inner layer is close to the skin and made of non-woven fabric; the middle layer is water-absorbent fluff pulp, added with polymer water-absorbing agent; the outer layer is an impermeable breathable film.
Attack on Roche! Atezolizumab slams PD-L1 drug market
Roche's Genentech said the company recruited 667 patients to participate in the clinical phase II study, and just a few weeks ago the company also released positive results for the drug to treat bladder cancer and said it would seek early approval for the indication. . At present, Roche has 11 clinical phase III studies on atezolizumab, and the company hopes to screen out the best indications so that atezolizumab can quickly occupy the market after its launch.
Roland's CMO Sandra Horning said it will release detailed research data in the near future. The researchers have only revealed some research details such as a reduction in tumors in some advanced patients in the study.
PD-L1 is called Programmed Death Ligand-1 (programmed death ligand-1) and is widely present on tumor cells. Tumor cells use this ligand to block the mutual recognition of B7.1 on PD-1 and T cells, thereby evading the monitoring of the immune system. Previously listed Opdivo and Keytruda have been proven to have excellent results and have attracted widespread attention in the industry. At present, giants such as Roche and AstraZeneca are constantly striving to make a difference in this field.
On the other hand, atezolizumab has a special meaning for Roche. In recent years, Roche has rarely listed breakthrough drugs, which can not help but make people feel like a thin mountain. The company currently urgent need for a heavyweight to prove his breakthrough drugs still are among the first echelon of the biomedical industry. Atezolizumab can take on this responsibility and let us wait and see.
Prev Article
Shelter is exposed to high temperature hazards.